Peripheral Nerve Repair
5% Dextrose Hydrodissection × PRP × Continuous Ultrasound GuidanceCarpal · cubital · sciatic · post-op nerve adhesion | Taiwan-led: Wu YT 2017 Mayo Clin Proc
"See the nerve" under ultrasound · 5% dextrose cumulative repair · no tissue damage
Wu 2017 / 2018 RCTs support D5W efficacy for CTS / ulnar entrapment · honest surgery referral when warranted
Your Nerve Repair Treatment Includes
Hydrodissection · physical separation of adhesions
Fluid cushion separates nerve from surrounding tissue · releases compression
5% dextrose · cumulative repair, non-damaging
Ultrasound-guided "see the nerve"
No pushing D5W to delay necessary surgery
When nerve conduction damage is severe, surgical referral is the honest call · D5W suits mild-to-moderate cases
※ Click any chip to view full scope and exclusion terms
From Inquiry to Follow-Up at a Glance
Submit Inquiry
Fill out the online form, or send photos via LINE
Personal Reply From the Doctor
After reviewing your details, the doctor shares an initial assessment and next steps
In-Person Evaluation
Palpation, ultrasound, and symptom scales — full recommendations given on the spot
Treatment Begins
A treatment plan tailored just for you
Ongoing Follow-Up
We track progress with assessment scales and adjust the dose to fit your response
Want a faster appointment? Here are a few ways
Share one of our posts publicly, and stay flexible for a visit within two weeks
Add our LINE, follow us on IG/FB and share a post, while keeping your schedule open for two weeks. Send us the screenshot when you book — the moment another patient cancels, we’ll call you to fill the slot first
Willing to let your case (no name, no face shown) be used as patient education
Sign the consent form and we’ll prioritize your consultation — your privacy is fully protected throughout
How to use: Please tell our booking staff via LINE message which option(s) you’d like to use — LINE leaves a written record so both sides stay aligned. In person works too, but please follow up with a quick LINE confirmation.
Fair use: To keep things fair to other patients — once priority scheduling is activated, please honor the matching commitment at your consultation (post stays public until your visit, consent form signed as agreed, responsive to standby notifications). If priority is activated but not fulfilled, you’ll return to the standard queue and future use of this option will need to be reassessed.
※ All of the above are entirely voluntary — choose one, several, or none. It won’t affect your care
* Typical timeline; may vary by individual case
Want to know which path fits your situation? Either way works — pick whichever feels easier.
Liusmed Clinic — Cross-Specialty Core Principles
From skin tumors to peripheral nerves, "you can only treat what you can see" is our unwavering creed. Perineural hydrodissection cannot afford "hitting the nerve itself" — ultrasound makes needle tip, nerve, and vessels simultaneously visible, the respect a nerve deserves.
Taiwan-Led · Seeing Nerves · Honest Triage
Taiwan's Strongest Research Team
For CTS 5% dextrose nerve hydrodissection, Taiwan leads globally — Tri-Service General Hospital Wu YT group 2017 Mayo Clin Proc (PMID:28734327) is a landmark RCT; Lin CP 2020 NMA (PMID:32197544) ranks D5W #1 by BCTQ-SSS. We stand on the shoulders of Taiwan's research.
Ultrasound-Guided "See the Nerve"
Perineural hydrodissection cannot afford "hitting the nerve itself" or "hitting a vessel." We use continuous US guidance — needle tip, nerve, and vessels all simultaneously visible. Accuracy rises from 50-80% (blind) to 95%+. Lin 2024 umbrella review (PMID:39219174) confirms US guidance consistently outperforms landmark.
No Pushing D5W to Delay Necessary Surgery
For mild-to-moderate CTS we strongly recommend D5W hydrodissection — the strongest evidence option. But for severe CTS (visible thenar atrophy, absent SNAP, DML > 8 ms), AAOS 2024 guideline clearly recommends direct surgery — we honestly tell you and refer to hand surgery. A responsible physician does not say "let's try D5W first" just to bill another session.
You Might Be Experiencing
The traditional path for peripheral neuropathy was "rest → brace → steroids → surgery." Repeated steroid injections can damage perineural tissue; surgery carries risk. Regenerative medicine offers a fourth path: 5 mL of 5% dextrose injected via fine needle along the epineurium to physically separate adhesions and deliver repair signals.
- Hand numb wakes you at night, shaking helps (classic CTS)
- Numbness in little and ring fingers (cubital tunnel syndrome)
- Tingling on wrist motion, grip weakness
- Buttock-to-posterior-thigh pain after sitting (piriformis/sciatica)
- Numbness returned post-surgery — thinking "another surgery" is the only answer
- Steroid tried but effect not lasting
Why Can 5 mL of Dextrose Improve Symptoms for 6+ Months?
When a nerve is compressed or adhered, it becomes ischemic, conducts slowly, and produces numbness and pain. "Nerve hydrodissection" uses fluid itself for physical separation, combined with 5% dextrose's special mechanism, achieving repair without steroid or tissue damage.
Hydrodissection: Physical Adhesion Separation
When a nerve is compressed or adhered to surrounding tendons, ligaments, or connective tissue, it becomes ischemic, conducts slowly, and produces numbness and pain. "Nerve hydrodissection" uses 5 mL of 5% dextrose injected via fine needle along the epineurium — **the fluid itself acts like "unzipping" to physically separate nerve from adhesion** — pure mechanical release, not drug or steroid.
5% Dextrose: Cumulative Repair, Non-Damaging
The 5% dextrose advantage is precisely "non-suppression" — unlike steroid, it does not depress perineural tissue causing long-term atrophy. It gently stimulates local TRPV1 receptors (pain modulation) and improves perineural nourishment. Wu 2018 RCT shows D5W superior to steroid at 4-6 months. "Better with more rounds" is D5W's nature — not true of steroid.
PRP: Advanced Option for Severe Cases
PRP (platelet-rich plasma) contains PDGF (Platelet-Derived Growth Factor), VEGF (Vascular Endothelial Growth Factor), IGF-1 (Insulin-like Growth Factor 1) growth factors providing direct repair signaling to perineural tissue. Wu 2017 Sci Rep RCT shows PRP outperforms control over 6 months for CTS; Shen 2019 RCT: PRP slightly superior to D5W on BCTQ-FSS and DML. But AAOS 2024 guideline states "strong evidence shows PRP does not provide long-term benefit for CTS" — so we position PRP as a "stronger mid-term (3-6 months) effect" option; long-term management requires patient preparation.
What the Studies Say — What It Means for You
We surface the 4 most pivotal studies on "nerve hydrodissection" — 3 of them from Taiwan. Each has "what it means for you" translating academic numbers into clinic-room questions.
D5W Hydrodissection vs PRP vs Steroid vs Surgery
| Item | D5W Hydrodissection (Our First Choice) | PRP | Steroid | Surgery |
|---|---|---|---|---|
| Mechanism | Physical adhesion separation + perineural nourishment + analgesia | Growth factors directly repair perineural tissue | Suppress inflammation, analgesia | Physically release transverse carpal ligament etc. |
| Evidence (CTS) | ★★★★ (NMA SMD #1, Wu 2017/2018 RCT) | ★★★ NMA (Network Meta-Analysis) #2; AAOS does not support long-term | ★★ short-term (≤3 mo, Cochrane 2023); not supported long-term | ★★★★ first-line for severe (AAOS 2024 strong) |
| Side Effects / Risks | Brief site distension < 24h, rare intraneural < 1% | 24-72h pain, bruising; 20-40% limited improvement | Repeat use atrophies perineural tissue, depigmentation (blind 11% vs US 3%) | Anesthesia, infection, nerve injury, recurrence (5-10%) |
| Repeatability | Repeatable (better with more) | Repeatable | Cochrane: 2nd injection no extra benefit | One-time (re-op risky) |
| Our Position | First-line for mild-moderate CTS/UNE; post-op recurrent | Stronger mid-term option (with AAOS dissent disclosed) | Short-term bridging for acute flare | Refer for severe CTS (thenar atrophy) |
Key Insight: D5W hydrodissection is not "cheaper steroid" — it is "a different category of therapy mechanistically better suited to long-term management." The best path for most patients: try D5W first (NMA #1) → add PRP if mid-term unsatisfactory → surgery only for severe. We will not push D5W to delay necessary surgery just to bill another session.
Why Liusmed Clinic Chose "D5W × Ultrasound Guidance"
We do not pitch a single magic bullet. Literature has long told us D5W nerve hydrodissection is the most effective non-surgical option for CTS, with ultrasound guidance making it safer. Two axes behind our choice:
Literature Support
- ·Wu YT 2017 Mayo Clin Proc (PMID:28734327): single 5 mL D5W significantly improves BCTQ-SSS, CSA, DML at 6 months (large effect). Taiwan Tri-Service Hospital leads globally.
- ·Wu YT 2018 Ann Neurol (PMID:30187524): D5W vs triamcinolone double-blind RCT, D5W superior to steroid at 4-6 months.
- ·Lin CP 2020 NMA (PMID:32197544): D5W ranked #1 by SMD on BCTQ-SSS and FSS; PRP #2; steroid #3.
- ·Chen LC 2020 RCT (PMID:32325164): UNE 6-month double-blind RCT, D5W superior to steroid from month 3 on symptom severity and nerve CSA reduction (p<0.05).
- ·Chao 2022 (PMID:35806998): post-op recurrent CTS D5W — mean 3.1 injections, 61.1% effective; "true recurrent" excellent outcome 61.6%.
Dr. Liu — Clinical Observations
- ·Ultrasound guidance lets us "see the nerve" — non-negotiable safety prerequisite for perineural hydrodissection. Needle tip, nerve, and vessels visible throughout, avoiding the worst complication: intraneural injection. "You can only treat what you can see" is Liusmed Clinic's cross-specialty creed.
- ·Many patients have "tried steroid a few times without lasting effect" — this is exactly what Cochrane 2023 wrote: "short-term effective, long-term ineffective." We will not keep pushing steroid; we tell you directly: D5W is a different therapy, different mechanism, different long-term outcome.
- ·For severe CTS (thenar atrophy, absent SNAP), AAOS 2024 clearly recommends direct surgery. We honestly say: "D5W may be too late at your severity; we recommend hand-surgery evaluation first; come back for post-op maintenance if needed." A responsible physician does not push patients to use D5W to delay necessary surgery.
- ·CTS post-op recurrence is a common "gray zone" — re-operation is risky and many patients are stuck. Chao 2022 gave us evidence-based answer: D5W mean 3.1 injections, 61.1% reach "effective" (≥50% improvement). Post-op recurrence does not always need re-surgery.
- ·We track via BCTQ-SSS, BCTQ-FSS, grip strength, ultrasound CSA at 2 wk / 1 mo / 3 mo / 6 mo. Objective numbers beat subjective feel — and this is what patients end up valuing most.
We did not pick the "newest, flashiest" — we picked the combination with the strongest current evidence, alignment with our cross-specialty philosophy, and the highest chance you can avoid (re-)surgery.
Treatment Process
From evaluation to follow-up, five stages ensuring precise triage and lasting effect
Clinic Evaluation
BCTQ + Tinel/Phalen + history
Ultrasound + NCS if needed
Nerve CSA, severity grading
Individualized Injectate Selection
D5W first; PRP advanced; severe → surgery
US-Guided Hydrodissection
Needle/nerve/vessel visible throughout
BCTQ/Grip Strength Follow-Up
2 wk / 1 mo / 3 mo / 6 mo
Clinical Evidence & References
5% dextrose nerve hydrodissection is "off-label." Taiwan research teams (Wu YT, Lin MT, Chang KV) lead globally with abundant peer-reviewed evidence. PRP for perineural hydrodissection is performed under Special Medical Technology Regulations; AAOS 2024 does not support long-term benefit. We explicitly disclose off-label status in informed consent and track each patient objectively via BCTQ, grip strength, and ultrasound CSA.
- [1]OCEBM 1b2017
Wu YT, et al.. Six-Month Efficacy of Perineural Dextrose for Carpal Tunnel Syndrome: A Prospective, Randomized, Double-Blind, Controlled Trial. Mayo Clin Proc 92(8):1179-1189.
Landmark RCT (Randomized Controlled Trial): D5W vs saline double-blind, single 5 mL injection significantly improves BCTQ-SSS, FSS, VAS (Visual Analog Scale), median nerve CSA, DML at 6 months (large effect). Taiwan research leading globally.
PMID: 28734327 - [2]OCEBM 1b2018
Wu YT, et al.. Six-month efficacy of perineural dextrose injection vs corticosteroid in carpal tunnel syndrome: A double-blind, randomized controlled trial. Ann Neurol 84(4):601-610.
D5W vs triamcinolone double-blind RCT: single injection followed for 6 months — D5W outperformed steroid at 4-6 months on BCTQ-SSS, nerve CSA, DML (p<0.05).
PMID: 30187524 - [3]OCEBM 1a2020
Lin CP, et al.. A Comparative Effectiveness of Different Injectates in Carpal Tunnel Syndrome: A Systematic Review and Network Meta-Analysis. Pharmaceuticals (Basel) 13(3):49.
Injectate network meta-analysis: D5W ranked #1 by SMD (Standardized Mean Difference) on BCTQ-SSS (symptom severity) and FSS (function); PRP #2; steroid #3.
PMID: 32197544 - [4]OCEBM 1b2020
Chen LC, et al.. Ultrasound-Guided 5% Dextrose Hydrodissection Versus Steroid Injection in Cubital Tunnel Syndrome: A Randomized Controlled Trial. Arch Phys Med Rehabil 101(8):1296-1303.
Cubital tunnel syndrome 6-month double-blind RCT (n=33): single-injection D5W vs triamcinolone — both effective; from month 3, D5W showed significantly greater symptom severity and nerve CSA reduction (p<0.05).
PMID: 32325164 - [5]OCEBM 2b2022
Chao TC, et al.. Ultrasound-Guided Perineural Injection with 5% Dextrose for Recurrent or Persistent Carpal Tunnel Syndrome After Surgery: A Retrospective Clinical Study. J Clin Med 11(13):3705.
Post-op recurrent/residual CTS D5W retrospective (n=36): mean 3.1 injections, mean 33-month follow-up; 61.1% reached "effective" (≥50% improvement); "true recurrent" excellent outcome 61.6% vs "persistent" 13% (p=0.006).
PMID: 35806998 - [6]OCEBM 1a2023
Ashworth NL, et al.. Local corticosteroid injection for carpal tunnel syndrome. Cochrane Database Syst Rev 2:CD015148.
Cochrane SR (Systematic Review): corticosteroid vs placebo for CTS — short-term (≤3 months) significantly effective (high-quality evidence); long-term (>3 months) insufficient or no benefit.
PMID: 36722795 - [7]OCEBM G2024
Shapiro LM, Kamal R, et al.. AAOS Clinical Practice Guideline: Management of Carpal Tunnel Syndrome. J Am Acad Orthop Surg 33(7):e356-e366.
AAOS 2024 CPG: Strong evidence shows PRP injection (LR or LP) does not provide long-term benefit for CTS (rated equivalent to steroid as "no long-term benefit"). Severe CTS still warrants surgery.
PMID: 39637428 - [8]OCEBM 1b2017
Maniquis-Smigel L, Reeves KD, et al.. Short Term Analgesic Effects of 5% Dextrose Epidural Injections for Chronic Low Back Pain. Anesth Pain Med 6(1):e42550.
32 chronic LBP with sciatica RCT: 10 mL D5W vs saline single caudal epidural; at 4h, 84% vs 19% achieved ≥50% pain reduction (p<0.001), still significant at 2 weeks (p=0.012).
Our Commitment to Honest Disclosure
Every procedure deserves your full understanding before deciding. The following summarizes common considerations and current research context; individual applicability is evaluated by the physician so you can proceed with confidence.
Contraindications
- •Active injection-site infection, severe coagulopathy
- •Complete nerve transection, cauda equina, progressive nerve deficit (surgical emergency)
- •Severe CTS (thenar atrophy, absent SNAP) — direct surgery recommended
- •Active malignancy, pregnancy (relative), injectate component allergy
Common Side Effects
- •D5W: transient site distension < 24h, occasional brief numbness flare < 1 week
- •PRP: 24-72h post-injection pain, bruising; 20-40% have limited improvement
- •Rare intraneural injection, bleeding, infection (< 1%; US guidance markedly reduces risk)
- •Diabetic patients: 5 mL 5% D5W contains 0.25 g glucose, minimal impact; still advise informing primary physician
Research Status & Clinical Observations
- •5% dextrose nerve hydrodissection is "off-label": labeled use is IV infusion; abundant peer-reviewed evidence supports its use (Wu 2017 Mayo Clin Proc, Lin CP 2020 NMA, Pan 2023 NMA), but off-label status must be explicitly disclosed in informed consent.
- •AAOS dissenting view on PRP long-term benefit for CTS: AAOS 2024 CPG states "strong evidence shows PRP does not provide long-term benefit for CTS," equivalent to steroid as "no long-term benefit." We honestly explain this guideline position and position PRP as "stronger mid-term (3-6 months) effect."
- •Honest disclosure of evidence-level stratification: D5W for CTS/UNE is Level I (multiple RCTs + meta-analyses); post-op recurrent CTS is Level II (Chao 2022 retrospective); caudal epidural D5W for sciatica is Level I-II; piriformis/deep gluteal US-guided perisciatic hydrodissection is Level III (case series). We tell you the evidence level for your location — no overclaiming.
Transparent Pricing Ranges
| Item | Price Range | Notes |
|---|---|---|
| Initial evaluation (BCTQ + US + NCS/EMG if needed) | From NT$ 800 | — |
| US-guided D5W nerve hydrodissection (single) | From NT$ 4,500 | Varies slightly by nerve site, dose, follow-up frequency |
| PRP perineural injection (advanced, stronger mid-term) | From NT$ 12,000 | Per Special Medical Technology Regulations; AAOS 2024 does not support long-term benefit — full disclosure required |
| Caudal epidural D5W (sciatica with LBP) | From NT$ 6,500 | Per case evaluation; rule out cauda equina |
Actual pricing depends on individual symptoms, treatment count, and custom formulation — quoted after physician evaluation. We commit to transparent pricing with no pushy upselling.
FAQ
5% Dextrose hydrodissection vs steroid — which is better?
Why this treatment in Taiwan? Is the Taiwan team really leading?
Can I avoid surgery for my carpal tunnel syndrome?
How soon will I feel improvement?
Is sciatica suitable?
I had the surgery, why is the numbness back?
Is 5% dextrose legal in Taiwan? Off-label?
Who should not have this treatment?
Dr. Ta-Ju Liu
Director, Liusmed Clinic · Over 20 years in minimally-invasive treatment
- Former attending dermatologist, Chang Gung Medical Center & Cosmetic Center
- Board-certified dermatologist · minimally-invasive surgery focus
- Advanced ultrasound-guided procedures · filler complication repair · complete apocrine gland clearance
"You can only treat what you can see" is the core belief running through every procedure I do. The subcutaneous world is intricate; what used to depend on experience and palpation now has a more reliable lens — advanced ultrasound. Seeing vessels, nerves, capsules, and glands first, then deciding where and how deep to cut — that is the standard every patient deserves.
Numbness Is Not Something to "Tough Out" — Let Us See the Nerve with Ultrasound First, Then Decide
We are not "injection machines." Every pre-injection evaluation, ultrasound localization, and conversation with you is designed so "you do not have to come back" or "you do not have to (re-)operate." Start with LINE consultation or book in-person.